ηγωεϊ εδεγςεϊ μςιϊεπεϊ
θας ξφιβδ ΰϊ ΰρθψθβιϊ δφξιηδ ωμδ μωπιν δαΰεϊ δηαψδ ηεωτϊ ξθψεϊ ΰρθψθβιεϊ ΰψελεϊ θεεη θας ξεγιςδ ςμ δωμξϊ δψλιωδ ωμ ηαψϊ χεβ'πριρ21/2/2008 αξδμκ ιεν ξωχιςιν ωςψλδ απιε ιεψχ, δφιβδ θας ΰϊ ςιχψι δϊελπιϊ δΰρθψθβιϊ ωμδ μωπιν δχψεαεϊ. λξε λο, δλψιζδ θας ςμ λεεπϊδ μδλτιμ ΰϊ ςρχι δηαψδ ςγ ωπϊ 2012, μδβις μξλιψεϊ ωμ 20 ξιμιΰψγ γεμψ εωιςεψ ψεεη πχι βαεδ ξςωψιν ΰηεζ. ςμ ξπϊ μδωιβ ξθψεϊ ΰμε, αλεεπϊ θας μξπσ ΰϊ ιϊψεπεϊιδ δϊηψεϊιιν: δτψιρδ δβμεαμιϊ ωμ δηαψδ, ρμ δξεφψιν δβγεμ εδξηειαεϊ μξεαιμεϊ ωεχ δβπψιχδ δςεμξι.
"ΰπε ωξηιν μδφιβ μξωχιςι δηαψδ ΰϊ ςιχψι δϊελπιϊ δΰρθψθβιϊ ωμπε μωπιν δαΰεϊ ςμ ξπϊ ωιελμε μδϊψων ξτεθπφιΰμ δφξιηδ δςεξγ ατπιπε", ΰξψ ωμξδ ιπΰι, πωιΰ εξπλ"μ θας. "τψρπε διεν ϊξεπδ ξτεψθϊ ωμ δδζγξπειεϊ, λιεεπι δτςεμδ δΰρθψθβιιν εξπεςι δφξιηδ ωμπε. ΰπε ξηειαιν μξεαιμεϊ ωεχ βμεαμιϊ ωμ δβπψιχδ, απερσ μδξωκ φξιηϊ δςρχιν δΰηψιν ωμπε, ϊεκ ωξιψδ ςμ ΰιλεϊ εψξϊ ωψεϊ βαεδδ".
ψλιωϊ χεβπριρ
απερσ, θας δεγιςδ διεν λι δωμιξδ ΰϊ ψλιωϊδ ωμ ηαψϊ χεβ'πριρ ,(CoGenesys Inc.) ηαψδ αιετψξφαθιϊ τψθιϊ ςν ϊωϊιϊ αϊηεν δαιεθλπεμεβιδ εΰωψ ξϊξχγϊ ατιϊεη ϊψετεϊ αιεμεβιεϊ αϊηεξι θιτεμ ωεπιν. χεβ'πριρ ϊωεμα ατςιμεϊ δαιετψξφαθιχδ δχιιξϊ ωμ θας.
ΰεγεϊ θας
θας ϊςωιεϊ τψξφαθιεϊ ας"ξ διπδ ηαψδ βμεαμιϊ ωαριρδ αιωψΰμ εΰηϊ ξ-20δηαψεϊ δτψξφαθιεϊ δξεαιμεϊ αςεμν. θας, δξϊξηδ αιιφεψ ϊψετεϊ βπψιεϊ ειιηεγιεϊ ειιφεψ ηεξψιν τςιμιν μϊςωιδ δτψξφαθιϊ, διπδ δηαψδ δξεαιμδ αςεμν αϊηεν δβπψιχδ. μθας ΰϊψι ιιφεψ, ξηχψ, ωιεεχ εδτφδ αιωψΰμ, αφτεο εαξψλζ ΰξψιχδ εαΰιψετδ. ιεϊψ ξ-80% ξξλιψεϊιδ ωμ δχαεφδ δο μφτεο ΰξψιχδ εΰιψετδ.
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva's ability to rapidly integrate CoGenesys' operations with its own operations, the diversion of management time on merger-related issues, and Teva and CoGenesys' ability to successfully develop and commercialize biopharmaceutical products, Teva's ability to accurately predict future market conditions, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra®, Neurontin®, Lotrel® Famvir®, and Protonix®, Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, the effects of competition on our innovative products, especially Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva's ability to rapidly integrate CoGenesys' operations with its own operations, the diversion of management time on merger-related issues, and Teva and CoGenesys' ability to successfully develop and commercialize biopharmaceutical products, Teva's ability to accurately predict future market conditions, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra®, Neurontin®, Lotrel® Famvir®, and Protonix®, Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, the effects of competition on our innovative products, especially Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
| © 1999 - 2008 λμ δζλειεϊ ωξεψεϊ μθας | ϊπΰι ωιξεω αΰϊψ | ξτϊ δΰϊψ |